Delcath Systems, INC

Delcath Systems, Inc. has updated its bylaws to designate exclusive forums for corporate and federal securities claims.

Delcath Systems reported Q2 2026 results, showing revenue growth and raising full-year revenue guidance, though adjusted EBITDA and operating cash flow saw a year-over-year decrease.

Delcath Systems, Inc. announced that its stockholders approved an amendment to its 2020 Omnibus Equity Incentive Plan to increase available shares and ratified the appointment of CBIZ CPAs P.C. as its independent auditor.

Delcath Systems announced first quarter 2026 financial results, with total revenue reaching $25.0 million, and provided full-year revenue guidance of at least $100 million.

Delcath Systems announced the publication of positive CHOPIN clinical trial results in The Lancet Oncology, highlighting the promise of combining percutaneous hepatic perfusion with immunotherapy for metastatic uveal melanoma.

Delcath Systems announced strong financial results for Q4 and full year 2025, with significant revenue growth and positive adjusted EBITDA, alongside an optimistic 2026 outlook.

Delcath Systems, Inc. announced its second quarter 2026 financial results, showcasing a significant increase in product revenue driven by HEPZATO sales and positive developments in ongoing clinical trials.

Delcath Systems, Inc. reported its first quarter 2026 financial results, showing a significant increase in revenue driven by its HEPZATO KIT product.

Delcath Systems, Inc. announced significant revenue growth and a positive shift to profitability for the nine months ended September 30, 2025, driven by HEPZATO and CHEMOSAT sales and promising clinical trial results.

Delcath Systems, Inc. reported a significant increase in product revenue and a shift to net income for the six months ended June 30, 2025, driven by the commercial expansion of HEPZATO KIT and CHEMOSAT.

Delcath Systems, Inc. reports a significant increase in revenue for Q1 2025, driven by the commercial expansion and demand for its HEPZATO KIT and CHEMOSAT products.

Delcath Systems saw a significant increase in revenue in the third quarter of 2024, primarily due to the commercial launch of its HEPZATO Kit in the U.S.

Delcath Systems, Inc. reported a significant increase in revenue for 2025, driven by the commercial expansion of HEPZATO KIT in the US and CHEMOSAT in Europe, alongside positive clinical trial results for combination therapies.

Delcath Systems' 10-K filing reveals a significant revenue increase driven by the commercial launch of HEPZATO KIT and continued CHEMOSAT sales in Europe.

Delcath Systems' 10-K filing details its capital structure, including common and preferred stock, outstanding warrants and options, and provides an overview of its regulatory environment and business risks.

Director John Richard Sylvester was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Director Bridget A. Martell was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Director Elizabeth Czerepak was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Director Steven A.J. Salamon was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Director Aharon Gil was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

DELCATH SYSTEMS, INC. CFO Sandra Pennell acquired 5,533 shares of common stock at $9.04 per share.

Delcath Systems, Inc. has issued its 2026 proxy statement, seeking stockholder approval for director elections, an increase in equity plan shares, and auditor ratification.

Delcath Systems, Inc. has filed a definitive proxy statement with the SEC.

Delcath Systems is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans at the upcoming annual meeting to enhance its ability to attract and retain key personnel.

Delcath Systems, Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Delcath Systems, Inc. is holding its 2024 Annual Meeting of Stockholders on May 23, 2024, to vote on key proposals including the election of a director, an amendment to the equity incentive plan, and the ratification of the company's auditor.

Rosalind Advisors and its affiliates updated their beneficial ownership in Delcath Systems, Inc., maintaining a 9.9% stake and confirming board appointments.

An amendment to a Schedule 13D filing reveals Rosalind Advisors and its affiliated funds continue to hold a substantial beneficial ownership in Delcath Systems, with key personnel Steven Salamon and Gil Aharon serving as independent directors on the company's board.

Rosalind Advisors, along with its affiliated funds and principals, filed an amended Schedule 13D disclosing their continued beneficial ownership of approximately 9.9% of Delcath Systems, Inc. common shares, while also confirming the 2020 appointments of Steven Salamon and Gilad Aharon to the company's Board of Directors.

Individual investor Daniel Kaufman has reported a 5.08% beneficial ownership stake in Delcath Systems, Inc., holding 1,766,432 shares of common stock.

BlackRock, Inc. has reported a 5.01% beneficial ownership stake in Delcath Systems Inc., holding 1,753,024 shares of common stock as of September 30, 2025.

Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC have filed an Amendment No. 2 to their Schedule 13G, disclosing a continued beneficial ownership of 2.2% of Delcath Systems, Inc.'s common stock as of March 31, 2025.